Rising Pharmaceuticals has launched a generic version of Lyrica, (pregabalin) Capsules in the US, in all eight commercially available strengths of 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg.

According to IMS Health, Pregabalin Capsules had sales of around $5.5bn in the US for the 12 months ending March 2019.

Pregabalin Capsules are used for management of neuropathic pain related to diabetic peripheral neuropathy, for the management of postherpetic neuralgia, for adjunctive therapy for the treatment of partial onset seizures in patients, aged four years and more, for the management of fibromyalgia, and for the management of neuropathic pain related to spinal cord injury.

Vimal Kavuru – CEO for Rising Pharmaceutical said: “The commercialization of Pregabalin Capsules is one of the largest volume launches for the company this year and will provide a cost effective treatment option for people living with debilitating neuropathic pain conditions.”

Rising Pharmaceuticals is the exclusive distributor for Laurus Labs, its development and manufacturing partner, which recently secured final approval from the US Food and Drug Administration (FDA) for the abbreviated new drug Application (ANDA) for the generic version of Pregabalin Capsules.

The company owned by Rising Pharma Holdings sells generic prescription products and over-the-counter pharmaceutical products under the Rising brand to wholesalers, distributors, chain drug stores,  and mass merchandisers. As of now, Rising Pharmaceuticals has more than 125 approved and commercial products in the US and a further 82 products pending launch or in development, representing a combined addressable market value of $12.5 billion.

  Laurus Labs, Lyrica, Pregabalin Capsules, Rising Pharma Holdings, Rising Pharmaceuticals, USA, Vimal Kavuru